查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球化學發光免疫分析市場：按產品（設備,消耗品）,技術（化學發光酵素,顆粒化學發光）,樣本類型（血液,尿液）,應用（傳染病,腫瘤）,最終用戶至2028預測
市場調查報告書
商品編碼
1306576

全球化學發光免疫分析市場：按產品（設備,消耗品）,技術（化學發光酵素,顆粒化學發光）,樣本類型（血液,尿液）,應用（傳染病,腫瘤）,最終用戶至2028預測

Chemiluminescence Immunoassay Market by Product (Instrument, Consumable), Technology (Chemiluminescence Enzyme, Microparticle Chemiluminescence), Sample (Blood, Urine), Application (Infectious Disease, Oncology), End User - Global Forecast to 2028
出版日期: | 出版商: MarketsandMarkets | 英文 276 Pages | 訂單完成後即時交付

價格
簡介目錄

預計 2023 年全球化學發光免疫分析市場規模為 132 億美元，預計到 2028 年將達到 190 億美元，預測期內復合年增長率為 7.5%。

艾滋病毒/艾滋病,肝炎,呼吸道感染和性傳播疾病等疾病需要準確,及時的診斷，以便進行有效的治療和管理。 化學發光免疫分析在診斷和監測這些感染方面發揮著重要作用，推動了該領域的市場增長。

“根據樣本類型，血液部分在預測期內顯示出最高的增長率”

從樣本類型來看化學發光免疫分析市場，血液樣本部分實現了顯著增長，例如獻血人數的增加，而慢性病和傳染病患病率的上升也支撐了血液樣本部分的增長。 據世界衛生組織稱，2020 年全球獻血量超過 1.185 億次。 世衛組織建議所有捐獻的血液在使用前進行傳染病檢測，特別是梅毒,艾滋病毒,瘧疾,乙型肝炎,乙型肝炎和丙型肝炎。

“從應用來看，腫瘤檢測領域將在預測期內實現最高增長率”

從應用來看化學發光免疫分析市場，腫瘤學領域預計將顯示出最高的增長率。 癌症檢測需求激增是由於多種因素造成的，包括癌症發病率上升,人們越來越重視癌症早期檢測和治療的需要以及癌症篩查工作的增加。

“亞太地區：按地區劃分增長最快的市場”

就按地區劃分的化學發光免疫分析市場而言，預計亞太地區在預測期內的複合年增長率最高。 中國和印度等該地區的新興經濟體，加上目標人群眾多，正在投資發展醫療保健基礎設施。 預計這將為在該地區運營的化學發光免疫分析公司提供重大的增長機會。

內容

第1章簡介

第 2 章研究方法

第 3 章執行摘要

第 4 章重要考慮因素

第5章市場概述

  • 簡介
  • 市場動態
    • 驅動程序
    • 制約因素
    • 機會
    • 任務
  • 價值鏈分析
  • 供應鏈分析
  • 波特五力分析
  • 主要利益相關者和採購標準
  • 監管狀況
  • 技術分析
  • 貿易分析
  • 生態系統映射
  • 專利分析
  • 重大會議和活動（2023-2024 年）
  • 價格分析
  • 影響客戶業務的趨勢/干擾

第 6 章化學發光免疫分析市場：副產品

  • 簡介
  • 消耗品
  • 設備

第 7 章化學發光免疫分析市場：按技術

  • 簡介
  • 化學發光酵素
  • 電化學發光免疫分析
  • 微粒化學發光免疫分析

第 8 章化學發光免疫分析市場：按樣品類型

  • 簡介
  • 血
  • 尿液
  • 唾液
  • 其他類型的樣本

第 9 章化學發光免疫分析市場：按應用

  • 簡介
  • 感染
  • 內分泌疾病
  • 腫瘤
  • 心髒病
  • 過敏診斷
  • 驗血
  • 自身免疫性疾病
  • 骨骼和礦物質疾病
  • 毒理學
  • 新生兒篩查
  • 治療藥物監測
  • 代謝紊亂
  • 消化系統疾病
  • 神經症
  • 呼吸系統疾病
  • 其他用途

第 10 章化學發光免疫分析市場：按最終用戶劃分

  • 簡介
  • 醫院
  • 臨床實驗室
  • 製藥和生物技術公司,CRO（合同研究組織）
  • 其他最終用戶

第11章化學發光免疫分析市場：按地區

  • 簡介
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 意大利
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 亞太地區其他地區
  • 其他地區
    • 拉丁美洲
    • 中東和非洲

第12章競爭格局

  • 概述
  • 主要公司採取的策略
  • 頂級公司的收入分析
  • 市場份額分析
  • 公司評估矩陣：主要公司
  • 企業評估矩陣：中小企業和初創企業
  • 競爭基準測試
  • 企業足跡分析
  • 競爭場景

第13章公司簡介

  • 主要公司
    • F. HOFFMANN-LA ROCHE LTD.
    • DANAHER CORPORATION
    • SIEMENS HEALTHINEERS AG
    • DIASORIN S.P.A.
    • ABBOTT LABORATORIES
    • SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
    • SYSMEX CORPORATION
    • DIATRON
    • GETEIN BIOTECH, INC.
    • WERFEN
    • QUIDELORTHO CORPORATION
    • EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG
  • 其他企業
    • MERCK KGAA
    • TOSOH CORPORATION (TOSOH BIOSCIENCE)
    • TRIVITRON HEALTHCARE
    • ABNOVA CORPORATION
    • ELABSCIENCE
    • MACCURA BIOTECHNOLOGY CO., LTD.
    • AUTOBIO DIAGNOSTICS CO., LTD
    • JIANGSU ZECEN BIOTECH CO., LTD
    • RAYTO LIFE AND ANALYTICAL SCIENCES CO., LTD.
    • DAAN GENE CO., LTD.
    • DYNEX TECHNOLOGIES, INC.
    • ZYBIO INC.
    • WIENER LABORATORIOS SAIC
    • TIANJIN ERA BIOLOGY TECHNOLOGY CO., LTD.

第14章 附錄

簡介目錄
Product Code: MD 8709

The chemiluminescence immunoassay market is valued at an estimated USD 13.2 billion in 2023 and is projected to reach USD 19.0 billion by 2028 at a CAGR of 7.5% during the forecast period. Diseases such as HIV/AIDS, hepatitis, respiratory infections and sexually transmitted infections, require an accurate and timely diagnosis for effective treatment and control. Chemiluminescence immunoassay plays a major role in the diagnosis and monitoring of these infectious diseases, driving the growth of the market in this area.

"Blood samples segment is projected to witness highest growth rate in the chemiluminescence immunoassay market, by sample type, during the forecast period"

The chemiluminescence immunoassay market is segmented into blood, urine, saliva, and other sample types. The blood segment in chemiluminescence immunoassay is experiencing significant growth, primarily driven by the increasing number of blood donations and the rising incidence of chronic and infectious diseases also support the growth of the blood samples segment. According to the WHO, in 2020, over 118.5 million blood donations were collected worldwide. The WHO recommends testing all donated blood for infections before use, especially syphilis, HIV, malaria, HBV, and hepatitis B and C.

"Oncology testing segment is projected to register highest growth rate in the chemiluminescence immunoassay market, by application, during the forecast period"

The global chemiluminescence immunoassay market is bifurcated into infectious diseases, endocrinology, oncology, bone & mineral disorders, cardiology, blood screening, autoimmune disorders, allergy diagnostics, toxicology, newborn screening, therapeutic drug monitoring, respiratory, neurology, metabolic disorders, gastroenterology, and other applications. Oncology testing segment is expected to grow at the highest rate within the chemiluminescence immunoassay market. The surge in demand for oncology testing is attributed to various factors such as rise in the incidence of cancer, increasing emphasis on the need for early detection and treatment of cancer, along with measures to increase cancer screening measures.

"Asia Pacific: The fastest-growing region chemiluminescence immunoassay market"

The global chemiluminescence immunoassay market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to register the highest CAGR during the forecast period. Emerging countries in Asia Pacific such as China and India have been investing in developing their healthcare infrastructure, coupled with the presence of large target population. These factors are expected to provide significant growth opportunities for chemiluminescence immunoassay companies operating in this region.

The break-up of the profile of primary participants in the chemiluminescence immunoassay market:

  • By Company Type: Tier 1 - 28%, Tier 2 - 41%, and Tier 3 - 31%
  • By Designation: C-level - 30%, D-level - 34%, and Others - 36%
  • By Region: North America - 37%, Europe - 28%, Asia Pacific - 20%, Rest of the World- 15%

The key players in this market are F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Siemens Healthineers AG (Germany), DiaSorin S.p.A. (Italy), Abbott Laboratories (US), Shenzhen Mindray Bio-medical Electronics Co., Ltd. (China), Sysmex Corporation (Japan), Diatron (Hungary), Getein Biotech, Inc. (China), Werfen (Spain), QuidelOrtho Corporation (US), EUROIMMUN (Germany), Merck KGaA (Germany), Tosoh Corporation (Japan), Trivitron Healthcare (India), Abnova Corporation (Taiwan), Elabscience (US), Maccura Biotechnology Co., Ltd. (China), Autobio Diagnostics Co., Ltd. (China), Jiangsu Zecen Biotech Co., Ltd (China), Rayto Life and Analytical Sciences Co., Ltd. (China), Daan Gene Co., Ltd. (China), DYNEX TECHNOLOGIES, Inc. (US), Zybio, Inc. (China), Wiener Laboratorios SAIC (Argentina), Tianjin Era Biology Technology Co., Ltd. (China).

Research Coverage:

This research report categorizes the chemiluminescence immunoassay market by product (consumables and instruments), technology (Chemiluminescence Enzyme Technology (CLEIA), Electrochemiluminescence immunoassay (ECLI), and Microparticle Chemiluminescence Immunoassay), sample type (blood, urine, saliva, and other sample types), application (infectious diseases, endocrinology, oncology, bone & mineral disorders, cardiology, blood screening, autoimmune disorders, allergy diagnostics, toxicology, newborn screening, therapeutic drug monitoring, respiratory, neurology, metabolic disorders, gastroenterology, and other applications), end user (hospitals, clinical laboratories, pharmaceuticals & biotechnology companies and contract research organizations, and other end users), and region (North America, Europe, Asia Pacific, and Rest of the World). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the chemiluminescence immunoassay market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; acquisitions, agreements. new product launches and approvals, and recent developments associated with the chemiluminescence immunoassay market. Competitive analysis of upcoming startups in the chemiluminescence immunoassay market ecosystem is covered in this report.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall chemiluminescence immunoassay market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

  • Analysis of key drivers (increasing incidences of chronic and infectious diseases, advances in improving the CLIA technologies, rising demand for point-of-care testing (POCT), growth of biotechnology and biopharmaceutical industries, growing geriatric population, and shift towards personalized medicine), restraints (high cost of CLIA systems and reagents and cross-reactivity and interference), opportunities (high growth prospects in emerging countries and collaborations and partnerships), and challenges (unfavorable reimbursement scenario and lack of skilled professionals) influencing the growth of the chemiluminescence immunoassay market
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the chemiluminescence immunoassay market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the chemiluminescence immunoassay market across varied regions.
  • Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the chemiluminescence immunoassay market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Seimens Healthineers AG (Germany), Abbott Laboratories (US), and DiaSorin S.p.A.(Italy), among others in the chemiluminescence immunoassay market strategies.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • FIGURE 1 CHEMILUMINESCENCE IMMUNOASSAY MARKET SEGMENTATION
    • 1.3.2 GEOGRAPHICAL SCOPE
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH APPROACH
    • FIGURE 2 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Primary sources
      • 2.1.2.2 Key data from primary sources
      • 2.1.2.3 Key industry insights
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY AND DEMAND SIDE PARTICIPANTS
    • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 5 REVENUE SHARE ANALYSIS ILLUSTRATION
    • FIGURE 6 MARKET ESTIMATION FROM IVD MARKET
    • FIGURE 7 MARKET ESTIMATION FROM IMMUNOASSAY MARKET
    • FIGURE 8 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS OF CHEMILUMINESCENCE IMMUNOASSAY MARKET
    • FIGURE 9 TOP-DOWN APPROACH
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 10 DATA TRIANGULATION METHODOLOGY
  • 2.4 MARKET SHARE ANALYSIS
  • 2.5 STUDY ASSUMPTIONS
  • 2.6 RESEARCH LIMITATIONS
  • 2.7 RISK ASSESSMENT
    • TABLE 1 RISK ASSESSMENT: CHEMILUMINESCENCE IMMUNOASSAY MARKET
  • 2.8 GROWTH RATE ASSUMPTIONS
  • 2.9 IMPACT OF RECESSION ON CHEMILUMINESCENCE IMMUNOASSAY MARKET

3 EXECUTIVE SUMMARY

    • FIGURE 11 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2023 VS. 2028 (USD BILLION)
    • FIGURE 12 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD BILLION)
    • FIGURE 13 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2023 VS. 2028 (USD BILLION)
    • FIGURE 14 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2023 VS. 2028 (USD BILLION)
    • FIGURE 15 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2023 VS. 2028 (USD BILLION)
    • FIGURE 16 GEOGRAPHICAL SNAPSHOT OF CHEMILUMINESCENCE IMMUNOASSAY MARKET

4 PREMIUM INSIGHTS

  • 4.1 CHEMILUMINESCENCE IMMUNOASSAY MARKET OVERVIEW
    • FIGURE 17 INCREASING INCIDENCE OF DISEASES AND TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET
  • 4.2 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT (2022)
    • FIGURE 18 CONSUMABLES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
  • 4.3 GEOGRAPHICAL GROWTH OPPORTUNITIES IN CHEMILUMINESCENCE IMMUNOASSAY MARKET
    • FIGURE 19 CHINA AND INDIA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
  • 4.4 CHEMILUMINESCENCE IMMUNOASSAY MARKET: REGIONAL MIX
    • FIGURE 20 ASIA PACIFIC TO WITNESS HIGHEST GROWTH RATE DURING STUDY PERIOD
  • 4.5 CHEMILUMINESCENCE IMMUNOASSAY MARKET: DEVELOPED VS. DEVELOPING MARKETS
    • FIGURE 21 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING STUDY PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 22 CHEMILUMINESCENCE IMMUNOASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing incidences of chronic and infectious diseases globally
    • FIGURE 23 INCREASING INCIDENCES OF DIABETES (GLOBAL)
    • FIGURE 24 NUMBER OF PEOPLE WITH CHRONIC CONDITIONS IN US, 1995-2030 (MILLION INDIVIDUALS)
      • 5.2.1.2 Advancements in improving chemiluminescence immunoassay technologies in recent years
      • 5.2.1.3 Growth of biotechnology and biopharmaceutical industries
      • 5.2.1.4 Rapid increase in geriatric population globally
    • FIGURE 25 GLOBAL GERIATRIC POPULATION, BY REGION, 2019 VS. 2050 (MILLION)
      • 5.2.1.5 Shift toward personalized medicines and individualized treatment decisions
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High cost of chemiluminescence systems and reagents
      • 5.2.2.2 Lack of regular quality control procedures for monitoring and detecting cross-reactivity and interference
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 High growth prospects for players in emerging economies
      • 5.2.3.2 Increasing number of collaborations and partnerships
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Unfavorable reimbursement scenario and budgetary constraints in healthcare systems
      • 5.2.4.2 Lack of skilled professionals and aging workforce
  • 5.3 VALUE CHAIN ANALYSIS
    • FIGURE 26 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
  • 5.4 SUPPLY CHAIN ANALYSIS
    • FIGURE 27 DIRECT DISTRIBUTION TO BE PREFERRED STRATEGY FOR PROMINENT COMPANIES
  • 5.5 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 2 HIGH CONSOLIDATION IN MARKET TO RESTRICT ENTRY OF NEW PLAYERS
    • 5.5.1 DEGREE OF COMPETITION
    • 5.5.2 BARGAINING POWER OF SUPPLIERS
    • 5.5.3 BARGAINING POWER OF BUYERS
    • 5.5.4 THREAT OF SUBSTITUTES
    • 5.5.5 THREAT OF NEW ENTRANTS
  • 5.6 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.6.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS
    • TABLE 3 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS
    • 5.6.2 BUYING CRITERIA
    • FIGURE 29 KEY BUYING CRITERIA FOR MAJOR END USERS
    • TABLE 4 KEY BUYING CRITERIA, BY END USER
  • 5.7 REGULATORY LANDSCAPE
    • 5.7.1 US
    • TABLE 5 US: CLASSIFICATION OF IMMUNOASSAY PRODUCTS
    • FIGURE 30 US: REGULATORY PROCESS FOR IVD DEVICES
    • 5.7.2 CANADA
    • FIGURE 31 CANADA: REGULATORY PROCESS FOR IVD DEVICES
    • 5.7.3 EUROPE
    • TABLE 6 EUROPE: CLASSIFICATION OF IVD DEVICES
    • 5.7.4 JAPAN
    • FIGURE 32 JAPAN: REGULATORY PROCESS FOR IVD DEVICES
    • TABLE 7 JAPAN: CLASSIFICATION OF IVD REAGENTS
    • TABLE 8 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
    • 5.7.5 CHINA
    • TABLE 9 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
    • 5.7.6 INDIA
    • FIGURE 33 INDIA: REGULATORY PROCESS FOR IVD DEVICES
    • 5.7.7 INDONESIA
    • TABLE 10 INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES
    • 5.7.8 RUSSIA
    • TABLE 11 RUSSIA: CLASSIFICATION OF IVD DEVICES
    • 5.7.9 SAUDI ARABIA
    • TABLE 12 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
    • 5.7.10 MEXICO
    • FIGURE 34 MEXICO: REGULATORY PROCESS FOR IVD DEVICES
    • TABLE 13 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
    • 5.7.11 BRAZIL
    • FIGURE 35 BRAZIL: REGULATORY PROCESS FOR IVD DEVICES
    • 5.7.12 SOUTH KOREA
    • TABLE 14 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
    • 5.7.13 MIDDLE EAST
    • 5.7.14 AFRICA
  • 5.8 TECHNOLOGY ANALYSIS
    • TABLE 15 RECENT PRODUCT LAUNCHES WITH ADVANCED TECHNOLOGIES IN CHEMILUMINESCENCE IMMUNOASSAY MARKET
  • 5.9 TRADE ANALYSIS
    • 5.9.1 TRADE ANALYSIS FOR CHEMILUMINESCENCE IMMUNOASSAYS
    • TABLE 16 IMPORT DATA FOR HS CODE 902780, BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 17 EXPORT DATA FOR HS CODE 902780, BY COUNTRY, 2018-2022 (USD MILLION)
  • 5.10 ECOSYSTEM MAPPING
    • FIGURE 36 ECOSYSTEM MAPPING OF CHEMILUMINESCENCE IMMUNOASSAY MARKET
    • 5.10.1 ROLE IN ECOSYSTEM
    • 5.10.2 KEY PLAYERS OPERATING IN CHEMILUMINESCENCE IMMUNOASSAY MARKET
  • 5.11 PATENT ANALYSIS
  • 5.12 KEY CONFERENCES AND EVENTS IN 2023-2024
    • TABLE 18 LIST OF CONFERENCES AND EVENTS IN 2023-2024
  • 5.13 PRICING ANALYSIS
    • 5.13.1 AVERAGE SELLING PRICE, BY APPLICATION (KEY PLAYERS)
    • TABLE 19 PRICE RANGE OFFERED BY KEY PLAYERS, BY APPLICATION (USD)
  • 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES

6 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
    • TABLE 20 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • 6.2 CONSUMABLES
    • 6.2.1 CONSUMABLES TO ACCOUNT FOR LARGEST SHARE OF CHEMILUMINESCENCE IMMUNOASSAY MARKET DURING STUDY PERIOD
    • TABLE 21 LIST OF CHEMILUMINESCENCE IMMUNOASSAY CONSUMABLES AVAILABLE
    • TABLE 22 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR CONSUMABLES, BY REGION, 2021-2028 (USD MILLION)
  • 6.3 INSTRUMENTS
    • 6.3.1 INCREASING ADVANCES WITH HIGH-THROUGHPUT CAPACITIES AND GROWING AUTOMATION TRENDS TO DRIVE MARKET
    • TABLE 23 LIST OF CHEMILUMINESCENCE IMMUNOASSAY INSTRUMENTS AVAILABLE
    • TABLE 24 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR INSTRUMENTS, BY REGION, 2021-2028 (USD MILLION)

7 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY

  • 7.1 INTRODUCTION
    • TABLE 25 CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • 7.2 CHEMILUMINESCENCE ENZYME
    • 7.2.1 HIGH RELIABILITY OF BLOOD TESTS IN CLINICAL DIAGNOSTICS AND PHARMACEUTICAL RESEARCH TO DRIVE MARKET
    • TABLE 26 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR CHEMILUMINESCENCE ENZYME, BY REGION, 2021-2028 (USD MILLION)
  • 7.3 ELECTROCHEMILUMINESCENCE IMMUNOASSAY
    • 7.3.1 INCREASED GENERATION OF EXCITED STATES THROUGH BETTER ELECTRODE VARIATION TO DRIVE MARKET
    • TABLE 27 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR ELECTROCHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2021-2028 (USD MILLION)
  • 7.4 MICROPARTICLE CHEMILUMINESCENCE IMMUNOASSAY
    • 7.4.1 HIGHER COSTS AND GREATER CHANCES OF CROSS-REACTIVITY DUE TO MULTIPLEXING TO LIMIT MARKET
    • TABLE 28 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR MICROPARTICLE CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2021-2028 (USD MILLION)

8 CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY SAMPLE TYPE

  • 8.1 INTRODUCTION
    • TABLE 29 CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
  • 8.2 BLOOD
    • 8.2.1 HIGH RELIABILITY OF BLOOD TESTS FOR IMMUNOASSAY DIAGNOSTIC PROCEDURES AND HEALTH SCREENING TO DRIVE MARKET
    • TABLE 30 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR BLOOD, BY REGION, 2021-2028 (USD MILLION)
  • 8.3 URINE
    • 8.3.1 INCREASING USE IN LAW ENFORCEMENT AND DRUG TESTING CENTERS TO DRIVE MARKET
    • TABLE 31 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR URINE, BY REGION, 2021-2028 (USD MILLION)
  • 8.4 SALIVA
    • 8.4.1 CONVENIENCE AND EASY TESTING OF BIOLOGICALLY ACTIVE PARTS OF HORMONES TO DRIVE MARKET
    • TABLE 32 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR SALIVA, BY REGION, 2021-2028 (USD MILLION)
  • 8.5 OTHER SAMPLE TYPES
    • TABLE 33 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2021-2028 (USD MILLION)

9 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION

  • 9.1 INTRODUCTION
    • TABLE 34 CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • 9.2 INFECTIOUS DISEASES
    • 9.2.1 RISING PREVALENCE OF INFECTIOUS DISEASES GLOBALLY AMONG ALL AGE GROUPS TO DRIVE MARKET
    • TABLE 35 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021-2028 (USD MILLION)
  • 9.3 ENDOCRINOLOGY
    • 9.3.1 RISING INCIDENCES OF DIABETES GLOBALLY TO DRIVE MARKET
    • TABLE 36 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR ENDOCRINOLOGY, BY REGION, 2021-2028 (USD MILLION)
  • 9.4 ONCOLOGY
    • 9.4.1 RISING BURDEN OF CANCER AND EMPHASIS ON EARLY DISEASE DIAGNOSIS TO DRIVE MARKET
    • TABLE 37 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
    • TABLE 38 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR ONCOLOGY, BY REGION, 2021-2028 (USD MILLION)
  • 9.5 CARDIOLOGY
    • 9.5.1 HIGH BURDEN OF CARDIOVASCULAR DISEASES AMONG ALL AGE GROUPS TO DRIVE MARKET
    • TABLE 39 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR CARDIOLOGY, BY REGION, 2021-2028 (USD MILLION)
  • 9.6 ALLERGY DIAGNOSTICS
    • 9.6.1 GROWING PREVALENCE OF ALLERGIES TO REGISTER INCREASED DEMAND FOR CHEMILUMINESCENCE IMMUNOASSAYS
    • TABLE 40 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR ALLERGY DIAGNOSTICS, BY REGION, 2021-2028 (USD MILLION)
  • 9.7 BLOOD SCREENING
    • 9.7.1 RISING VOLUME OF BLOOD DONATIONS AND INCREASING INCIDENCES OF BLOOD-RELATED DISORDERS TO DRIVE MARKET
    • TABLE 41 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR BLOOD SCREENING, BY REGION, 2021-2028 (USD MILLION)
  • 9.8 AUTOIMMUNE DISORDERS
    • 9.8.1 GROWING PREVALENCE OF AUTOIMMUNE DISORDERS AND RISING ECONOMIC BURDEN OF DISEASE MANAGEMENT TO DRIVE MARKET
    • TABLE 42 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR AUTOIMMUNE DISORDERS, BY REGION, 2021-2028 (USD MILLION)
  • 9.9 BONE & MINERAL DISORDERS
    • 9.9.1 HIGH DISORDER PREVALENCE TO INDICATE STRONG GROWTH OPPORTUNITIES FOR IMMUNOASSAYS
    • TABLE 43 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR BONE & MINERAL DISORDERS, BY REGION, 2021-2028 (USD MILLION)
  • 9.10 TOXICOLOGY
    • 9.10.1 INCREASED DRUG-OF-ABUSE TESTING AND HIGHER ILLICIT DRUG CONSUMPTION TO DRIVE MARKET
    • TABLE 44 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR TOXICOLOGY, BY REGION, 2021-2028 (USD MILLION)
  • 9.11 NEWBORN SCREENING
    • 9.11.1 CHEMILUMINESCENCE IMMUNOASSAYS TO BE ROUTINELY USED AS FIRST-TIER NEWBORN SCREENING PROTOCOL
    • TABLE 45 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR NEWBORN SCREENING, BY REGION, 2021-2028 (USD MILLION)
  • 9.12 THERAPEUTIC DRUG MONITORING
    • 9.12.1 RAPID DETECTION TIME AND GOOD SPECIFICITY TO DRIVE MARKET
    • TABLE 46 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR THERAPEUTIC DRUG MONITORING, BY REGION, 2021-2028 (USD MILLION)
  • 9.13 METABOLIC DISORDERS
    • 9.13.1 RISING PREVALENCE OF METABOLIC DISORDERS TO DRIVE MARKET
    • FIGURE 37 GLOBAL INCIDENCE OF DIABETES
    • TABLE 47 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR METABOLIC DISORDERS, BY REGION, 2021-2028 (USD MILLION)
  • 9.14 GASTROENTEROLOGY
    • 9.14.1 INCREASING INCIDENCE OF GASTROINTESTINAL TRACT INFECTIONS AND SERIOUS GASTRIC DISEASES TO DRIVE MARKET
    • TABLE 48 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR GASTROENTEROLOGY, BY REGION, 2021-2028 (USD MILLION)
  • 9.15 NEUROLOGY
    • 9.15.1 EFFECTIVE DETECTION, MONITORING, AND MANAGEMENT OF NEUROLOGICAL DISORDERS TO DRIVE SEGMENT
    • TABLE 49 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR NEUROLOGY, BY REGION, 2021-2028 (USD MILLION)
  • 9.16 RESPIRATORY
    • 9.16.1 EASY DETECTION AND DIAGNOSIS OF RESPIRATORY DISEASES TO DRIVE MARKET
    • TABLE 50 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR RESPIRATORY, BY REGION, 2021-2028 (USD MILLION)
  • 9.17 OTHER APPLICATIONS
    • TABLE 51 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)

10 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER

  • 10.1 INTRODUCTION
    • TABLE 52 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.2 HOSPITALS
    • 10.2.1 GROWING PATIENT POPULATION AND TESTING VOLUMES TO DRIVE MARKET
    • TABLE 53 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR HOSPITALS, BY REGION, 2021-2028 (USD MILLION)
  • 10.3 CLINICAL LABORATORIES
    • 10.3.1 RISING CLINICAL TEST VOLUMES AND REQUIREMENTS TO DRIVE SEGMENT
    • TABLE 54 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY REGION, 2021-2028 (USD MILLION)
  • 10.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS
    • 10.4.1 RISING DRUG DISCOVERIES AND CLINICAL STUDIES TO DRIVE MARKET
    • TABLE 55 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021-2028 (USD MILLION)
  • 10.5 OTHER END USERS
    • TABLE 56 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR OTHER END USERS, BY REGION, 2021-2028 (USD MILLION)

11 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY REGION

  • 11.1 INTRODUCTION
    • TABLE 57 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 11.2 NORTH AMERICA
    • FIGURE 38 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET SNAPSHOT
    • TABLE 58 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 59 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 60 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 61 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
    • TABLE 62 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 63 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.2.1 IMPACT OF ECONOMIC RECESSION ON NORTH AMERICA
    • 11.2.2 US
      • 11.2.2.1 US to hold largest share in North American chemiluminescence immunoassay market during forecast period
    • TABLE 64 US: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 65 US: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 66 US: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
    • TABLE 67 US: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 68 US: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.2.3 CANADA
      • 11.2.3.1 Rising government initiatives and funding for early disease diagnosis to drive market
    • TABLE 69 CANADA: ESTIMATED PREVALENCE OF DIABETES
    • TABLE 70 CANADA: MACROECONOMIC INDICATORS
    • TABLE 71 CANADA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 72 CANADA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 73 CANADA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
    • TABLE 74 CANADA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 75 CANADA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.3 EUROPE
    • TABLE 76 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 77 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 78 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 79 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
    • TABLE 80 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 81 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.3.1 IMPACT OF ECONOMIC RECESSION ON EUROPE
    • 11.3.2 GERMANY
      • 11.3.2.1 Growing investments in clinical diagnostics research and increasing government spending on healthcare to drive market
    • TABLE 82 GERMANY: MACROECONOMIC INDICATORS
    • TABLE 83 GERMANY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 84 GERMANY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 85 GERMANY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
    • TABLE 86 GERMANY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 87 GERMANY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.3.3 FRANCE
      • 11.3.3.1 Favorable reimbursement policies and increased investments in diagnostics to drive market
    • TABLE 88 FRANCE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 89 FRANCE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 90 FRANCE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
    • TABLE 91 FRANCE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 92 FRANCE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.3.4 UK
      • 11.3.4.1 Increasing number of accredited clinical laboratories and growing accessibility to IVD tests to drive market
    • TABLE 93 UK: MACROECONOMIC INDICATORS
    • TABLE 94 UK: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 95 UK: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 96 UK: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
    • TABLE 97 UK: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 98 UK: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.3.5 ITALY
      • 11.3.5.1 Growing geriatric population and increasing support for research to drive market
    • TABLE 99 ITALY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 100 ITALY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 101 ITALY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
    • TABLE 102 ITALY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 103 ITALY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.3.6 SPAIN
      • 11.3.6.1 Rising adoption of technologically advanced immunoassay systems to drive market
    • TABLE 104 SPAIN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 105 SPAIN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 106 SPAIN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
    • TABLE 107 SPAIN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 108 SPAIN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.3.7 REST OF EUROPE
    • TABLE 109 REST OF EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 110 REST OF EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 111 REST OF EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
    • TABLE 112 REST OF EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 113 REST OF EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.4 ASIA PACIFIC
    • FIGURE 39 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET SNAPSHOT
    • TABLE 114 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 115 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 116 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 117 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
    • TABLE 118 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 119 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.4.1 IMPACT OF ECONOMIC RECESSION ON ASIA PACIFIC
    • 11.4.2 JAPAN
      • 11.4.2.1 Growing investments in clinical diagnostics research to drive market
    • TABLE 120 JAPAN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 121 JAPAN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 122 JAPAN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
    • TABLE 123 JAPAN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 124 JAPAN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.4.3 CHINA
      • 11.4.3.1 China to register highest growth rate in Asia Pacific chemiluminescence immunoassay market during study period
    • TABLE 125 CHINA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 126 CHINA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 127 CHINA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
    • TABLE 128 CHINA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 129 CHINA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.4.4 INDIA
      • 11.4.4.1 Growing medical tourism and healthcare infrastructure to drive market
    • TABLE 130 INDIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 131 INDIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 132 INDIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
    • TABLE 133 INDIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 134 INDIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.4.5 SOUTH KOREA
      • 11.4.5.1 Rising healthcare spending for innovative IVD technologies to drive market
    • TABLE 135 SOUTH KOREA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 136 SOUTH KOREA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 137 SOUTH KOREA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
    • TABLE 138 SOUTH KOREA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 139 SOUTH KOREA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.4.6 REST OF ASIA PACIFIC
    • TABLE 140 REST OF ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 141 REST OF ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 142 REST OF ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
    • TABLE 143 REST OF ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 144 REST OF ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.5 REST OF THE WORLD
    • TABLE 145 REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 146 REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 147 REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 148 REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
    • TABLE 149 REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 150 REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.5.1 IMPACT OF ECONOMIC RECESSION ON REST OF THE WORLD
    • 11.5.2 LATIN AMERICA
      • 11.5.2.1 Rising incidence of infectious diseases and increasing geriatric population to drive market
    • TABLE 151 LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 152 LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 153 LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
    • TABLE 154 LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 155 LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.5.3 MIDDLE EAST & AFRICA
      • 11.5.3.1 Lack of skilled laboratory personnel and unfavorable reimbursement policies to limit market
    • TABLE 156 MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 157 MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 158 MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
    • TABLE 159 MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 160 MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)

12 COMPETITIVE LANDSCAPE

  • 12.1 OVERVIEW
  • 12.2 STRATEGIES ADOPTED BY KEY PLAYERS
    • TABLE 161 OVERVIEW OF STRATEGIES ADOPTED BY KEY MANUFACTURERS OF CHEMILUMINESCENCE IMMUNOASSAY PRODUCTS
  • 12.3 REVENUE ANALYSIS OF TOP MARKET PLAYERS
    • FIGURE 40 REVENUE ANALYSIS OF TOP MARKET PLAYERS IN CHEMILUMINESCENCE IMMUNOASSAY MARKET
  • 12.4 MARKET SHARE ANALYSIS
    • TABLE 162 CHEMILUMINESCENCE IMMUNOASSAY MARKET: DEGREE OF COMPETITION
    • FIGURE 41 CHEMILUMINESCENCE IMMUNOASSAY MARKET SHARE, BY KEY PLAYER (2022)
  • 12.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS
    • 12.5.1 STARS
    • 12.5.2 EMERGING LEADERS
    • 12.5.3 PERVASIVE PLAYERS
    • 12.5.4 PARTICIPANTS
    • FIGURE 42 CHEMILUMINESCENCE IMMUNOASSAY MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS
  • 12.6 COMPANY EVALUATION MATRIX FOR SMES/START-UPS
    • 12.6.1 PROGRESSIVE COMPANIES
    • 12.6.2 STARTING BLOCKS
    • 12.6.3 RESPONSIVE COMPANIES
    • 12.6.4 DYNAMIC COMPANIES
    • FIGURE 43 CHEMILUMINESCENCE IMMUNOASSAY MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES
  • 12.7 COMPETITIVE BENCHMARKING
    • TABLE 163 CHEMILUMINESCENCE IMMUNOASSAY MARKET: DETAILED LIST OF KEY START-UPS/SMES
  • 12.8 COMPANY FOOTPRINT ANALYSIS
    • TABLE 164 OVERALL COMPANY FOOTPRINT
    • TABLE 165 COMPANY PRODUCT FOOTPRINT
    • TABLE 166 COMPANY REGIONAL FOOTPRINT
  • 12.9 COMPETITIVE SCENARIO
    • 12.9.1 KEY PRODUCT LAUNCHES AND APPROVALS
    • TABLE 167 CHEMILUMINESCENCE IMMUNOASSAY MARKET: KEY PRODUCT LAUNCHES AND APPROVALS, 2020-2023
    • 12.9.2 KEY DEALS
    • TABLE 168 CHEMILUMINESCENCE IMMUNOASSAY MARKET: KEY DEALS, 2020-2023
    • 12.9.3 OTHER KEY DEVELOPMENTS
    • TABLE 169 CHEMILUMINESCENCE IMMUNOASSAY MARKET: OTHER KEY DEVELOPMENTS, 2020-2023

13 COMPANY PROFILES

  • 13.1 KEY PLAYERS
  • (Business Overview, Products/Solutions Offered, Recent Developments, SWOT Analysis, Winning Imperatives, Current Focus and Strategies, Threat From Competition, Right to Win)**
    • 13.1.1 F. HOFFMANN-LA ROCHE LTD.
    • TABLE 170 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
    • FIGURE 44 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
    • 13.1.2 DANAHER CORPORATION
    • TABLE 171 DANAHER CORPORATION: COMPANY OVERVIEW
    • FIGURE 45 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
    • 13.1.3 SIEMENS HEALTHINEERS AG
    • TABLE 172 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
    • FIGURE 46 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022)
    • 13.1.4 DIASORIN S.P.A.
    • TABLE 173 DIASORIN S.P.A.: COMPANY OVERVIEW
    • FIGURE 47 DIASORIN S.P.A.: COMPANY SNAPSHOT (2022)
    • 13.1.5 ABBOTT LABORATORIES
    • TABLE 174 ABBOTT LABORATORIES: COMPANY OVERVIEW
    • FIGURE 48 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022)
    • 13.1.6 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
    • TABLE 175 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY OVERVIEW
    • FIGURE 49 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY SNAPSHOT (2021)
    • 13.1.7 SYSMEX CORPORATION
    • TABLE 176 SYSMEX CORPORATION: COMPANY OVERVIEW
    • FIGURE 50 SYSMEX CORPORATION: COMPANY SNAPSHOT (2022)
    • 13.1.8 DIATRON
    • TABLE 177 DIATRON: COMPANY OVERVIEW
    • FIGURE 51 STRATEC SE: COMPANY SNAPSHOT (2022)
    • 13.1.9 GETEIN BIOTECH, INC.
    • TABLE 178 GETEIN BIOTECH, INC.: COMPANY OVERVIEW
    • 13.1.10 WERFEN
    • TABLE 179 WERFEN: COMPANY OVERVIEW
    • 13.1.11 QUIDELORTHO CORPORATION
    • TABLE 180 QUIDELORTHO CORPORATION: COMPANY OVERVIEW
    • FIGURE 52 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2022)
    • 13.1.12 EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG
    • TABLE 181 EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG: COMPANY OVERVIEW
  • *Business Overview, Products/Solutions Offered, Recent Developments, SWOT Analysis, Winning Imperatives, Current Focus and Strategies, Threat From Competition, Right to Win might not be captured in case of unlisted companies.
  • 13.2 OTHER PLAYERS
    • 13.2.1 MERCK KGAA
    • 13.2.2 TOSOH CORPORATION (TOSOH BIOSCIENCE)
    • 13.2.3 TRIVITRON HEALTHCARE
    • 13.2.4 ABNOVA CORPORATION
    • 13.2.5 ELABSCIENCE
    • 13.2.6 MACCURA BIOTECHNOLOGY CO., LTD.
    • 13.2.7 AUTOBIO DIAGNOSTICS CO., LTD
    • 13.2.8 JIANGSU ZECEN BIOTECH CO., LTD
    • 13.2.9 RAYTO LIFE AND ANALYTICAL SCIENCES CO., LTD.
    • 13.2.10 DAAN GENE CO., LTD.
    • 13.2.11 DYNEX TECHNOLOGIES, INC.
    • 13.2.12 ZYBIO INC.
    • 13.2.13 WIENER LABORATORIOS SAIC
    • 13.2.14 TIANJIN ERA BIOLOGY TECHNOLOGY CO., LTD.

14 APPENDIX

  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS